Drug General Information
Drug ID
D0B5UH
Drug Name
ALX-0761
Drug Type
Monoclonal antibody
Indication Psoriasis [ICD9: 696; ICD10:L40] Phase 1 [889400]
Company
Ablynx
Target and Pathway
Target(s) Interleukin-17 Target Info Modulator [889442]
Interleukin-17 ligand Target Info Modulator [889442]
KEGG Pathway Cytokine-cytokine receptor interaction
Inflammatory bowel disease (IBD)
Rheumatoid arthritishsa04060:Cytokine-cytokine receptor interaction
Rheumatoid arthritis
NetPath Pathway TCR Signaling Pathway
PANTHER Pathway Interleukin signaling pathway
Pathway Interaction Database IL27-mediated signaling events
IL23-mediated signaling events
WikiPathways TCR Signaling Pathway
Allograft Rejection
IL17 signaling pathwayWP69:TCR Signaling Pathway
IL17 signaling pathway
References
Ref 889400ClinicalTrials.gov (NCT02156466) Multiple Ascending Dose Trial of MSB0010841 (Anti-IL17A/F Nanobody) in Psoriasis Subjects
Ref 889442Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801. doi: 10.1038/nrd4478.

If you find any error in data or bug in web service, please kindly report it to Dr. Wang and Dr. Li.